Table 1 Concentration of antigen-specific IgG necessary to achieve 99%, 80% and 50% target TBA with anti-Pfs230 and anti-Pfs25 antibodies, in hosts with different levels of parasite exposures: 1 oocysts/mosquitoes (low), 5 oocysts/mosquito (medium), 20 oocysts/mosquito (high).

From: Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations

   

Target TBA

99% TBA

80% TBA

50% TBA

Parasite exposure

1

Anti-Pfs230

3.29 µg/ml

2.33 µg/ml

1.18 µg/ml

Anti-Pfs25

7.50 µg/ml

4.89 µg/ml

2.81 µg/ml

5

Anti-Pfs230

4.07 µg/ml

2.89 µg/ml

1.45 µg/ml

Anti-Pfs25

10.37 µg/ml

6.89 µg/ml

3.75 µg/ml

20

Anti-Pfs230

9.54 µg/ml

6.43 µg/ml

3.14 µg/ml

Anti-Pfs25

/

23.19 µg/ml

8.18 µg/ml

  1. This table is intended to show how future human antibodies can be directly compared as avidity between mouse and human antibodies may vary.